The European Commission's decision on approval is expected in the second half of January 2025. Eylea is used to treat neovascular age-related macular degeneration and other severe retinal diseases.

Germany’s Formycon (ETR: FYB) and its licensing partner Klinge Biopharma have announced that the European Commission (EC) has granted central marketing authorization for FYB203 (aflibercept), a ...

"Millions of packages moved away from SurePost and the United States Postal Service and returned to UPS package cars this month, now being sorted and delivered by hardworking UPS Teamsters." ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application on track for a mid-2025 US launch. This positions it to compete effe ...

Regeneron’s lead drug, Eylea (aflibercept), is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. To counter the ongoing decline in Eylea sales ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...

Earlier on Monday, Regeneron shared preliminary results from the fourth quarter that showed Eylea HD generated just $305 million in the U.S. It was a stunning drop-off from the $392 million the ...

Total Eylea sales were $1.495 billion in the final quarter of 2024, coming in 1% ahead of the $1.478 billion expectation, according to the BMO note. Meanwhile, sales of the drug’s more recently ...

Primarily, the lower-than-expected sales figures for Eylea’s high dose in the fourth quarter raised concerns, as revenues fell short of both his and market consensus estimates. This ...